STOCK TITAN

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated news page for CRISPR Therapeutics (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRISPR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRISPR Therapeutics's position in the market.

Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at Citi 2024 Virtual Oncology Leadership Summit, offering a live webcast and replay option for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
conferences
-
Rhea-AI Summary
CRISPR Therapeutics (CRSP) secures $280 million investment to advance clinical trials and gene writing programs, strengthening balance sheet with over $2.1 billion in pro forma cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
offering
-
Rhea-AI Summary
CRISPR Therapeutics receives conditional marketing authorization from the European Commission for CASGEVY, a gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Over 8,000 eligible patients in the EU may benefit from this approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
Rhea-AI Summary
The U.S. FDA has approved CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older. CRISPR Therapeutics, the biopharmaceutical company behind the treatment, is working with Vertex Pharmaceuticals to establish a network of treatment centers throughout the U.S. to offer CASGEVY to eligible patients. This approval reflects the power and versatility of the CRISPR platform to bring potentially curative treatment options to patients suffering from devastating diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
-
Rhea-AI Summary
CRISPR Therapeutics (CRSP) highlights 2024 outlook, strategic priorities, and recent achievements, including the first-ever approval of a CRISPR-based gene-editing therapy and entering the clinic with in vivo therapies. The company plans to expand its pipeline, drive clinical trials, and innovate on its platform with next-generation gene editing and delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
conferences
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
fda approval
-
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
fda approval
-
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) provided an update on its immuno-oncology pipeline, focusing on next-generation CAR T product candidates CTX112™ targeting CD19 and CTX131™ targeting CD70. Preliminary data from ongoing clinical trials suggest that these candidates may improve upon the clinical profile of first-generation candidates CTX110 and CTX130, with increased CAR T cell expansion and functional persistence. The Company is transitioning patients treated with CTX110 and CTX130 to long-term follow-up and plans to expand trials of CTX112 into autoimmune disease and CTX131 into hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

CRSP Stock Data

6.56B
78.42M
1.34%
64.12%
19.82%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Zug

About CRSP

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.